One-shot weight loss: Can gene therapy actually replace the GLP-1 revolution?
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau 54% of participants on the 24 mg dose achieved resolution of obesity (BMI <30 kg/m2) vs. 13% in the placebo group […]
One-shot weight loss: Can gene therapy actually replace the GLP-1 revolution?
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.
Why exercise is essential for restoring fitness after GLP-1-based weight loss
This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, improves physical function and cardiorespiratory fitness after diet-induced weight loss in adults with obesity. In contrast, liraglutide alone sustains weight loss but does not significantly improve measured physical fitness outcomes.
The future GLP-1 might be a gene therapy: Report
As GLP-1 pills for weight loss enter the U.S. market, some pharmaceutical companies are testing the possibility of a gene therapy to stimulate GLP-1 production, The Washington Post reported Jan. 24. GLP-1 medications, such as Ozempic, Mounjaro, Wegovy and Zepbound, mimic a naturally occurring gut hormone to suppress appetite, promote a feeling of fullness, stimulate […]
Menopause Hormone Therapy May Boost GLP-1 Drug Benefits
(MedPage Today) — Postmenopausal women on the GLP-1 medication tirzepatide (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated. Among 120 women with overweight or obesity…
Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Diabetic Rats
Diabetes Mellitus (DM) is a rapidly increasing disease around the world. It is known that DM is associated with numerous complications which affect life quality by its debilitating nature. DM is associated with cognitive impairment and neurodegeneration, partly driven by neuroinflammation and disrupted neuronal signalling. Incretin-based treatments have recently been suggested to exert potential effects […]
Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics
A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong its monopoly against generic competition for the GLP-1 drug Victoza.
How LIR Life Sciences is making GLP-1 therapy easier to access worldwide
This content was created by Hive Labs in partnership with Fairfax Partners on behalf of LIR Life Sciences Corp. Treating obesity isn’t always as simple as telling someone to lose weight, and with the World Obesity Federation estimating that nearly four billion people worldwide will be affected by overweight and obesity by 2035, the need […]